Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “SGLT-2 Inhibitor”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT03087773
What this trial is testing

Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction

Who this might be right for
Acute Myocardial Infarction
Medical University of Graz 476
Large-scale testing (Phase 3)Looking for participantsNCT06024746
What this trial is testing

Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)

Who this might be right for
Heart Failure
Colorado Prevention Center 1,500
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07749014
What this trial is testing

Timing of Empagliflozin in Primary PCI: Pre-Reperfusion Versus Post-Reperfusion Versus Placebo in South Asian STEMI Patients

Who this might be right for
ST-elevation Myocardial Infarction (STEMI)Acute Myocardial Infarction (AMI)Coronary Artery Disease
Rehman Medical Institute - RMI 480
Post-approval studies (Phase 4)Study completedNCT02397421
What this trial is testing

Safety and Effectiveness of SGLT-2 Inhibitors in Patients With Heart Failure and Diabetes

Who this might be right for
Heart FailureDiabetes
University of Dundee 56
Not applicableUnknownNCT05520684
What this trial is testing

Asymptomatic Bacteriuria, Urinalysis Abnormality at the Initiation of SGLT2 Inhibitors and UTI Risk

Who this might be right for
Type2diabetes, SGLT2 Inhibitor, Urinary Tract Infection
Trabzon Arakli Bayram Halil Public Hospital 120
Testing effectiveness (Phase 2)Looking for participantsNCT07239011
What this trial is testing

Dapagliflozin in Depression

Who this might be right for
Depression
Tanta University 60
Large-scale testing (Phase 3)Looking for participantsNCT07038356
What this trial is testing

Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure

Who this might be right for
Acute Decompensated Heart Failure (ADHF)
Christian Schulze 536
Post-approval studies (Phase 4)Looking for participantsNCT04662723
What this trial is testing

Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.

Who this might be right for
GlomerulonephritisImmunoglobulin A Nephropathy
Fondazione Schena 878
Post-approval studies (Phase 4)Not Yet RecruitingNCT07527390
What this trial is testing

CANagliflozin In DIALysis Patients

Who this might be right for
DialysisChronic Kidney Disease (Stages 4 and 5)
University Medical Center Groningen 10
Not applicableStudy completedNCT07269197
What this trial is testing

Association of SGLT2 Inhibitors Therapy With Elastographic and Molecular Markers of Liver Injury in Type 2 Diabetes

Who this might be right for
Non-Alcoholic Fatty Liver DiseaseDiabetes Mellitus, Type 2
Josip Juraj Strossmayer University of Osijek 67
Large-scale testing (Phase 3)Looking for participantsNCT05345327
What this trial is testing

SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes

Who this might be right for
Type 2 Diabetes
The George Institute 994
Not applicableActive Not RecruitingNCT07694596
What this trial is testing

SGLT2 Inhibitors and Cognitive Function in Adults With Type 2 Diabetes (SaveMinD)

Who this might be right for
Type 2 Diabetes Mellitus (T2DM)Cognitive Dysfunction
University of Primorska 200
Not applicableStudy completedNCT04735042
What this trial is testing

SGLT-2 and DPP-4 Inhibition, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections.

Who this might be right for
Type 2 DiabetesUrinary Tract Infections
University of Pisa 60
Post-approval studies (Phase 4)Study completedNCT04461041
What this trial is testing

Empagliflozin and Cardiac Remodelling in People Without Diabetes

Who this might be right for
Cardiovascular DiseasesLeft Ventricular Hypertrophy
Unity Health Toronto 169
Post-approval studies (Phase 4)Study completedNCT06825156
What this trial is testing

Metabolic and Renal Outcomes in Cardiac Surgery Patients Receiving SGLT2 Inhibitors

Who this might be right for
Acute Kidney Injury
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) 60
Testing effectiveness (Phase 2)Looking for participantsNCT06182839
What this trial is testing

Canagliflozin in Advanced Renal Disease With MRI Endpoints

Who this might be right for
ESRD, CKD Stage 4, CKD Stage 5
McGill University Health Centre/Research Institute of the McGill University Health Centre 92
Post-approval studies (Phase 4)Study completedNCT02798744
What this trial is testing

SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation.

Who this might be right for
Diabetes Mellitus, Type 2
University of Leicester 68
Testing effectiveness (Phase 2)UnknownNCT05314725
What this trial is testing

Treatment With SGLT-2 Inhibitor for Postoperative Hyperglycemia in Acute Abdominal Surgery - a Randomized Trial

Who this might be right for
Postoperative HyperglycemiaStress Hyperglycemia
Zealand University Hospital 24
Testing effectiveness (Phase 2)Study completedNCT05757791
What this trial is testing

Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)

Who this might be right for
Major Depressive Disorder
NYU Langone Health 20
Large-scale testing (Phase 3)WithdrawnNCT07057479
What this trial is testing

Phase III Trial of SGLT2 Inhibitor and Thiazolidinedione Fixed-Dose Combination vs. Monotherapy in Type 2 Diabetes Patients on Metformin

Who this might be right for
Type 2 Diabetes Mellitus (T2DM)
Eurofarma Laboratorios S.A.
Next Page